# InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

> **NCT05463796** · — · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 5000 (estimated)

## Conditions studied

- Cancer Risk
- Cancer Predisposition Syndrome
- Hereditary Cancer Prediction
- Childhood Cancer Survivors
- Adult Cancer Survivors
- IARC Carcinogens
- Smoking History
- Lung Cancer
- Ductal/Lobular Carcinoma
- Barrett Esophagus
- Pancreatic Precursor Lesions
- Colonic Dysplasia/Adenomata
- Non-Alcoholic Fatty Liver Disease
- Non Alcoholic Steatohepatitis
- Cirrhosis
- High Grade Prostatic Epithelial Neoplasia
- High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ
- Adenomatous Hyperplasia
- High-risk Oral Precancerous Diseases
- Melanocytic Lesion, Adult
- Hematologic Malignancy
- Lung; Node
- Serous Tubal Intraepithelial Carcinoma
- Endometrial Intraepithelial Neoplasia
- Cervical and Endocervical Carcinoma in Situ
- Vulvar Intraepithelial Neoplasia
- Nephrogenic Rests
- Benign Bone Lesions With Risk of Malignant Degeneration
- Giant Cell Tumor
- Osteochondroma
- Spitz Nevus

## Interventions

- **OTHER:** Samples

## Key facts

- **NCT ID:** NCT05463796
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-25
- **Primary completion:** 2027-03-25
- **Final completion:** 2032-03-25
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05463796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05463796, "InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05463796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*